Molnupiravir is a nucleoside analogue that is N4-hydroxycytidine in which the 5'-hydroxy group is replaced by a (2-methylpropanoyl)oxy group. It is the prodrug of the active antiviral ribonucleoside analog N4-hydroxycytidine (EIDD-1931), has activity against a number of RNA viruses including SARS-CoV-2, MERS-CoV, and seasonal and pandemic influenza viruses. It is currently in phase III trials for the treatment of patients with COVID-19. It has a role as an anticoronaviral agent, an antiviral drug and a prodrug. It is a ketoxime, an isopropyl ester and a nucleoside analogue. It is functionally related to a N(4)-hydroxycytidine.